Core Insights - The company is a leading player in the global medical cannabis market, with a strong focus on international markets and compliance with stringent regulatory standards [1][3][23] - The company reported a 7% increase in net revenue, driven by a 12% growth in global medical cannabis revenue, with international sales growing by 17% [3][17] - The company is strategically exiting lower-margin consumer cannabis markets in Canada to focus on higher-margin medical cannabis operations [4][5][14] Financial Performance - Adjusted gross margin increased by 100 basis points to 62%, with medical cannabis margins at 69% due to growth in higher-margin international markets [2][16] - Adjusted EBITDA was reported at $18.5 million, with adjusted net income of $7.2 million and positive free cash flow of $15.5 million [2][17] - The company ended the quarter with $154 million in cash and no cannabis-related debt, maintaining a strong balance sheet [2][20] Market Strategy - The company is reallocating resources from the Canadian consumer cannabis segment to enhance its global medical cannabis business, which is expected to drive profitability [4][5][14] - The company plans to divest its lower-margin plant propagation operations to focus on higher-margin segments [5][32] - The company is expanding its product offerings in key international markets, including Germany and Australia, to capture growth opportunities [6][10][12] International Market Insights - Germany is highlighted as a significant market, with imports expected to double in 2025, driving the company's international revenue growth [7][9] - The Australian market is seen as a $1 billion opportunity, with efforts to shift sales towards premium products to improve margins [9][10] - The company is actively exploring new international markets, including Switzerland, Austria, and Turkey, to expand its footprint [50][57] Future Outlook - Annual global medical cannabis net revenue is projected to increase to between $269 million and $281 million, driven by 10% to 15% growth in the global medical cannabis segment [21][20] - Consolidated adjusted EBITDA is anticipated to grow by 5% to 10% year-over-year, reflecting the company's focus on high-margin medical cannabis operations [21][20] - The company is committed to maintaining its leadership position in the global medical cannabis market while exploring strategic opportunities for growth [23][46]

Financial Data and Key Metrics Changes - Net revenue increased by 7% to CAD 94.2 million, driven by a record 12% growth in global medical cannabis revenue, including a 17% increase internationally [4][16] - Adjusted gross margin rose by 100 basis points to 62%, with adjusted gross profit reaching CAD 55.6 million, a 6% increase [16] - Adjusted EBITDA was CAD 18.5 million, and adjusted net income was CAD 7.2 million, with positive free cash flow of CAD 15.5 million [5][17] - The company ended the quarter with CAD 154 million in cash and no cannabis business-related debt [5][17] Business Line Data and Key Metrics Changes - Medical cannabis net revenue rose by 12% to CAD 76.2 million, comprising 81% of total net revenue, compared to 77% in the prior year [17] - Consumer cannabis net revenue decreased by 48% to CAD 5.2 million, reflecting the strategic shift to focus on higher-margin global medical cannabis [18] - Bevo's plant propagation net revenue increased by 27% to CAD 11.3 million, but adjusted gross margin fell to 16% from 40% due to increased costs [19] Market Data and Key Metrics Changes - The German market, as the largest individual medical cannabis market in Europe, was a primary driver of double-digit growth in international revenue [8][9] - Australia is the largest international medical cannabis market for the company, with a potential AUD 1 billion opportunity, where the company holds the number two market share [11] - In Poland, the company maintained its number one position in market share, benefiting from increased annual import limits [13] Company Strategy and Development Direction - The company is focusing on exiting select markets within the lower Canadian consumer cannabis segment to prioritize higher-margin global medical cannabis [7] - A divestiture of the lower-margin plant propagation operations is planned to allocate capital more effectively and improve profitability [7] - The company aims to enhance its leadership position in global medical cannabis by solidifying its market presence in Canada, Europe, Australia, and New Zealand, while exploring new markets [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's competitive position in the global medical cannabis market, projecting significant growth opportunities [4][23] - The company anticipates annual global medical cannabis net revenue to increase to between CAD 269 million and CAD 281 million, driven by 10%-15% growth in the segment [21][22] - Management acknowledged potential headwinds in some markets but remains optimistic about the overall growth trajectory [55] Other Important Information - The company filed a prospectus supplement to establish a new At-the-Market equity program, allowing it to issue and sell up to $100 million of common shares [8] - The company is committed to maintaining high-quality standards in its products, with 90% of annual manufacturing capacity produced in GMP-certified facilities [6] Q&A Session Summary Question: Follow-up on the select market exit in Canada - Management indicated that exiting these markets will be beneficial to overall financial results and will allow for resource reallocation to international markets [25][27] Question: Impact of premiumization strategy in Australia - Management stated that the shift towards premium products is not disruptive and is expected to enhance margins [29][30] Question: Strategic decision to exit plant propagation - Management emphasized the focus on global medical cannabis as the most profitable area and the rationale behind divesting the plant propagation business [37][39] Question: Contribution of plant propagation to EBITDA - Management noted that the financial results of the plant propagation business will be treated as discontinued operations going forward [40] Question: Navigating regulatory changes in Poland - Management highlighted the company's strong relationships with regulators and its ability to adapt to changes in the regulatory environment [42][43] Question: Clarity on global medical cannabis revenue guidance - Management clarified that the guidance reflects total revenue, including the impact of the divestiture of Bevo [48][49] Question: Reasons for higher wholesale gross margins compared to consumer cannabis - Management explained that the consumer cannabis market is tight, leading to lower margins, while wholesale products are less available globally due to regulatory requirements [56][57] Question: Potential assets for M&A - Management expressed interest in cultivation capacity and other aspects of global medical cannabis, remaining opportunistic with the funds raised [61][62] Question: Supply chain and cultivation capacity - Management confirmed that nearly all products sold are produced in-house, with a focus on maintaining high-quality GMP flower [75][78]